Top

Journal of Hepato-Biliary-Pancreatic Sciences

Published in:

01-03-2011 | Original article

Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer

Authors: Masayuki Sho, Toshihiro Tanaka, Takatsugu Yamada, Takeo Nomi, Takahiro Akahori, Jin Doh, Ichiro Yamato, Daisuke Hokuto, Hideyuki Nishiofuku, Nagaaki Marugami, Hiromichi Kanehiro, Kimihiko Kichikawa, Yoshiyuki Nakajima

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 2/2011

Abstract

Background/Purpose

It has been reported recently that adjuvant gemcitabine prolonged postoperative disease-free survival in patients with resectable pancreatic cancer. However, the efficacy was limited and further studies are required to improve the prognosis. In particular, postoperative hepatic recurrence often occurs even after gemcitabine treatment.

Methods

We are currently trying to evaluate the efficacy of postoperative combination therapy of high-dose 5-fluorouracil (5-FU) arterial infusion with systemic gemcitabine. Patients received weekly high-dose 5-FU through the hepatic artery using a port-catheter system (1000 mg/m² for 5 h) plus concurrent systemic gemcitabine (1000 mg/m²).

Results

Thirty-one patients were enrolled and 29 patients (94%) completed the scheduled adjuvant chemotherapy. The toxicity was acceptable and this regimen was well feasible as an outpatient treatment. At the time of analysis, 21 patients (68%) had recurrence. Local recurrence was most frequently observed, in 43% of the patients with recurrence. On the other hand, hepatic recurrence developed in only 2 patients (10%). The 1-year disease-free rate and overall survival rate were 62.9 and 100%, respectively.

Conclusion

Our novel adjuvant strategy had a significant beneficial effect on early hepatic recurrence and may have the potential to prolong the overall survival of pancreatic cancer patients.

Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.PubMedCrossRef

Traverso LW. Pancreatic cancer: surgery alone is not sufficient. Surg Endosc. 2006;20(Suppl 2):S446–9.PubMedCrossRef

Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247:456–62.PubMedCrossRef

Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701–6.PubMedCrossRef

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed

Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, et al. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006;107:676–85.PubMedCrossRef

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.PubMedCrossRef

Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.PubMedCrossRef

Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A, Salvia R, et al. The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP. 2007;8:132–40.PubMed

10.

Hirano S, Kondo S, Hara T, Ambo Y, Tanaka E, Shichinohe T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Ann Surg. 2007;246:46–51.PubMedCrossRef

11.

Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36:159–65.PubMedCrossRef

12.

Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195–200.PubMedCrossRef

13.

Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas. 2005;31:69–73.PubMedCrossRef

14.

Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, et al. Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg. 2009;394:249–53.PubMedCrossRef

15.

Shimada K, Sakamoto Y, Sano T, Kosuge T. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg. 2006;203:345–52.PubMedCrossRef

16.

Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.PubMedCrossRef

17.

Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Tamamoto T, et al. Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study. AJR Am J Roentgenol. 2007;189:421–8.PubMedCrossRef

18.

Tanaka T, Sakaguchi H, Sho M, Yamamoto K, Nishiofuku H, Nakajima Y, et al. A novel interventional radiology technique for arterial infusion chemotherapy against advanced pancreatic cancer. AJR Am J Roentgenol. 2009;192:W168–77.PubMedCrossRef

19.

Beger HG, Gansauge F, Buchler MW, Link KH. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg. 1999;23:946–9.PubMedCrossRef

20.

Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg. 2002;236:806–13.PubMedCrossRef

21.

Kurosaki I, Kawachi Y, Nihei K, Tsuchiya Y, Aono T, Yokoyama N, et al. Liver perfusion chemotherapy with 5-fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. Pancreas. 2009;38:161–7.PubMedCrossRef

22.

Takeda S, Inoue S, Kaneko T, Harada A, Nakao A. The role of adjuvant therapy for pancreatic cancer. Hepatogastroenterology. 2001;48:953–6.PubMed

23.

Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas. 2002;25:366–72.PubMedCrossRef

24.

Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg. 1994;168:361–4.PubMedCrossRef

25.

Ishikawa O, Ohigashi H, Imaoka S, Sasaki Y, Kameyama M, Nakamori S, et al. Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepatogastroenterology. 1997;44:1541–6.PubMed

26.

Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88–95.PubMedCrossRef

27.

Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000;60:6075–9.PubMed

28.

Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, et al. Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer. 2003;39:1547–51.PubMedCrossRef

Title: Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer
Authors: Masayuki Sho
Toshihiro Tanaka
Takatsugu Yamada
Takeo Nomi
Takahiro Akahori
Jin Doh
Ichiro Yamato
Daisuke Hokuto
Hideyuki Nishiofuku
Nagaaki Marugami
Hiromichi Kanehiro
Kimihiko Kichikawa
Yoshiyuki Nakajima
Publication date: 01-03-2011
Publisher: Springer Japan
Published in: Journal of Hepato-Biliary-Pancreatic Sciences / Issue 2/2011
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-010-0336-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer

Abstract

Background/Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background/Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

Using the greater omental flap to cover the cut surface of the liver for prevention of delayed gastric emptying after left-sided hepatobiliary resection: a prospective randomized controlled trial

Pancreaticoduodenectomies with a duct-to-mucosa pancreaticojejunostomy anastomosis with and without a stenting tube showed no differences in long-term follow-up

Diagnostic procedures for IgG4-related sclerosing cholangitis

Robot-assisted laparoscopic pancreaticoduodenectomy

Allopurinol and xanthine oxidase inhibition in liver ischemia reperfusion

Donor quality of life after living donor liver transplantation: a prospective study